Emerson Electric Co.

(New York Stock Exchange)
Back to all articles
Neutral +5

Emerson Electric Co. (EMR) is Attracting Investor Attention: Here is What You Should Know

AI-generated analysis

📈 Emerson Electric (EMR) shares returned +14.2% over the past month, outperforming the S&P 500's +6.4% gain and the Manufacturing - Electronics sector's +11.4%.

💰 Analysts project quarterly earnings of $1.55 per share, representing a +4.7% increase from the same quarter last year.

📊 The consensus earnings estimate for the current fiscal year stands at $6.51, marking an +8.5% growth from the prior year.

🚀 Long-term projections show next fiscal year earnings expected at $7.13, indicating a +9.6% rise from a year ago.

⚖️ Zacks Rank #3 (Hold) suggests EMR may perform in line with the broader market due to recent earnings estimate revisions.

💵 Current quarterly sales are forecasted at $4.6 billion, with an estimated year-over-year growth of +3.7%.

📈 Fiscal year revenue estimates total $18.87 billion for the current year and $19.84 billion for next year, showing +4.7% and +5.2% growth respectively.

⚡ The company reported last quarter's revenues at $4.35 billion, beating consensus by -0.12%, while EPS surprise was +3.55%.

📉 Over the last four quarters, EMR surpassed consensus EPS estimates three times but only beat revenue estimates once.

📉 Zacks Value Style Score of D indicates the stock is trading at a premium compared to its industry peers.

📊 Historical P/E, P/S, and P/CF comparisons suggest investors should evaluate whether the current price reflects intrinsic value.

🔮 The analysis concludes that while EMR attracts attention, its fundamental metrics point toward average near-term performance.

👉 Readers can access a free stock analysis report or download the 7 Best Stocks for the Next 30 Days from Zacks.

Bullish Signals
  • Shares of Emerson Electric returned +14.2% in the past month, significantly outperforming the S&P 500 composite's +6.4% gain and the Manufacturing - Electronics industry average.
  • The company is expected to post current quarter earnings of $1.55 per share, indicating a positive change of +4.7% from the year-ago quarter.
  • For the current fiscal year, the consensus earnings estimate of $6.51 points to an improvement of +8.5% from the prior year.
  • Emerson reported actual revenues of $4.35 billion in the last quarter, representing a positive year-over-year change of +4.1%.
  • The company exceeded the consensus EPS estimate by +3.55% in its most recent reporting period, having surpassed estimates three times over the last four quarters.
  • Forward earnings growth is projected at +9.6% for the next fiscal year with a sales estimate increase of +5.2%.
Risk Factors
  • The stock is rated a neutral 'Hold' with Zacks Rank #3, suggesting it may perform in line with the broader market rather than outperforming in the near term.
  • Emerson Electric is graded D on the Zacks Value Style Score, indicating it is trading at a premium to its peers and potentially overvalued relative to valuation metrics.
  • Over the last four quarters, the company topped consensus revenue estimates only once, while surpassing consensus EPS estimates three times, highlighting recurring underperformance in top-line sales growth.
Full Analysis
Emerson Electric Co. (EMR) has recently attracted investor attention, with shares rising 14.2% over the past month compared to a 6.4% gain for the S&P 500 and an 11.4% gain for the Manufacturing - Electronics industry where EMR is classified. The company, known for producing process control systems, valves, and analytical instruments, is currently under analysis by Zacks Investment Research, which emphasizes evaluating changes in earnings projections to determine fair value and future price direction. Analysts track how sell-side estimates are revised in response to business trends, noting that a higher consensus estimate relative to the current market price typically drives buying interest and upward price movement. According to current earnings consensus estimates for EMR, the company is expected to report $1.55 per share for the current quarter, representing a 4.7% increase from the previous year. For the full fiscal year, the consensus estimate stands at $6.51, an 8.5% rise from the prior year, while the next fiscal year's projection of $7.13 indicates a 9.6% growth rate over what is expected for last year. Over the last 30 days, the quarterly earnings estimate changed by +0.2%, the annual estimate adjusted slightly by -0.1%, and the next-year estimate saw a minor decrease of -0.4%. Revenue performance remains a critical indicator for EMR's financial health, with consensus estimates showing the current quarter sales at $4.6 billion, a 3.7% year-over-year increase. Full fiscal year projections are set at $18.87 billion and $19.84 billion for the current and next fiscal years respectively, representing growth of 4.7% and 5.2%. The company reported actual revenues of $4.35 billion in the last quarter, beating the consensus estimate by -0.12%, while earnings per share (EPS) of $1.46 exceeded expectations with a 3.55% surprise. Historically, EMR has surpassed EPS estimates in three out of the last four quarters but has only topped revenue estimates once during this same period. Valuation analysis places EMR at a Zacks Rank #3 (Hold), suggesting it may perform in line with the broader market in the near term based on earnings estimate revisions and other factors. The company is graded D on the Zacks Value Style Score, indicating that its stock is currently trading at a premium compared to peers when evaluating price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF) metrics against historical values and industry comparables. While EMR has demonstrated strong earnings growth, the current valuation suggests the market is pricing it higher than its historical average, which investors should consider when weighing the recent market buzz alongside fundamental factors for potential long-term investment decisions.